Does Wegovy Work for Everyone? What the Evidence Shows

Step 1: understanding what the trial data actually says about response rates

The STEP 1 trial (published in the New England Journal of Medicine) randomised adults with obesity and no diabetes to semaglutide 2.4 mg or placebo over 68 weeks. The average weight reduction in the active group was around 15%. That figure is widely quoted, and it is genuinely impressive. But averages flatten a wide distribution. Some participants lost considerably more; others lost less, and a small proportion lost very little despite completing the course.

This is not a flaw in the medicine. It reflects how any treatment interacts with human biology at scale. The proportion of people who achieved at least 5% weight loss was high, but not universal. Whether everyone loses weight on Wegovy is its own question worth looking at separately, because the full picture of the distribution matters as much as the headline average.

NICE's appraisal of semaglutide for weight management (TA875) reviewed this evidence and recommended it within specialist services for eligible adults, accepting that variable response is part of the clinical picture. Their guidance includes a review point: if less than 5% weight loss has occurred after six months on the maintenance dose, continuing treatment should be reconsidered.

Step 2: the biological and personal factors that shape your response

Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, you can read more about the mechanism on our page explaining how Wegovy works. Because this pathway is one piece of a complex metabolic system, individuals differ in how strongly they respond.

Relevant factors include baseline metabolic rate, insulin sensitivity, gut-hormone receptor density and how the body adapts over time. Age is also a consideration, if you are wondering about the age-related criteria for Wegovy, there is separate guidance on that. Genetics appear to influence GLP-1 receptor sensitivity, though this is not yet clinically actionable: no blood test currently predicts your individual response before you start.

Lifestyle factors interact with the medicine rather than being replaced by it. Physical activity, protein intake and sleep quality all affect outcomes. None of this is about willpower; these are measurable biological variables. The medicine reduces appetite significantly for most people, but the degree of that reduction, and how the body uses the resulting energy deficit, varies.

One often-overlooked factor is dose. The licensed maintenance dose of 2.4 mg is reached after a titration period, and some people find the dose escalation slower than expected because of side effects. If the maintenance dose is never fully established, the expected benefit is reduced. That is not a personal failing; it is a clinical management question.

Step 3: when Wegovy does not seem to be working, and what can be done

There is an important distinction between Wegovy not working and Wegovy not having been given the conditions to work. A prescriber will look at whether the full titration was completed, whether lifestyle support is in place, whether other medicines or conditions might be interfering, and whether the timeline is realistic. Six months at maintenance dose is the meaningful assessment window, which is why the NICE guidance uses that checkpoint.

Some people find that Wegovy genuinely produces a limited response even at the full dose with full adherence. There is a dedicated resource on what happens when Wegovy does not work for those who want more detail on this. In those cases, a prescriber may discuss whether a different medicine, such as tirzepatide (Mounjaro), might be more appropriate. You can explore the broader weight-loss treatment options available through a private regulated pharmacy.

Side effects are the other main reason for sub-optimal results. Nausea, digestive discomfort and fatigue are common, especially during dose escalation. Most settle within a few weeks. If they do not, a prescriber may slow the titration rather than stopping treatment entirely. For those concerned about specific side effects such as hair changes on Wegovy, these are addressed separately. Worth knowing: what happens to weight if you eventually stop is a separate question, and the evidence on weight regain after stopping Wegovy is worth reading before you make any decision about duration.

Step 4: what this means before you start treatment

Knowing that semaglutide does not work identically for everyone is genuinely useful, not as a reason for pessimism, but as a reason to approach it with realistic expectations and proper clinical oversight. If you have been on treatment for a couple of months and feel discouraged, the titration schedule may simply not be complete yet. If you are comparing your results to someone else's, that comparison probably does not account for the ten variables that explain the difference.

For anyone thinking about private treatment, the practical starting point is a consultation. If you order before noon on a weekday (and many people find a Monday order fits neatly into the start of a new week), treatment that is clinically approved is dispatched the same day by our GPhC-registered pharmacy. The full Wegovy overview covers the treatment in detail, and if you are weighing up where to access it, our guide to buying Wegovy safely explains what to look for in a regulated provider. These are prescription medicines, the consultation is where suitability is properly established.

Speak to our prescribers if you would like a same-day clinical review from a GPhC-registered Independent Prescriber. Start your free consultation here.